This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Healy, A. M. Articles by Garasic, J. Search for Related Content PubMed Articles by Healy, A. M. Articles by Garasic, J. Related Collections Gene expression Thrombosis risk factors Acute myocardial infarction Platelets

(Circulation. 2007;115:e187.)
© 2007 American Heart Association, Inc.

Correspondence

Response to Letter Regarding Article, "Platelet Expression Profiling and Clinical Validation of Myeloid-Related Protein-14 as a Novel Determinant of Cardiovascular Events"

Aileen M. Healy, PhD; Michael D. Pickard, MA; Andrew I. Damokosh, PhD; Tracy L. Dowie, BS; Louis Poisson, MS; James Lillie, PhD

Millennium Pharmaceuticals, Inc, Cambridge, Mass

Aruna D. Pradhan, MD; Peter Libby, MD; Paul M Ridker, MD

Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass

Yunmei Wang, PhD; Zhiping Chen, MS; Kevin Croce, MD, PhD; Masashi Sakuma, MD; Can Shi, PhD; Alexandre C. Zago, MD; Daniel I. Simon, MD

Division of Cardiovascular Medicine, Case Cardiovascular Center, University Hospitals–Case Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio

Joseph Garasic, MD

Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Mass

An extract of the first 100% of the full text is provided, because this article has no abstract.

We would like to thank Dr Krishnan and colleagues for their interest in our work. They have raised additional limitations of our work and question whether platelets express myeloid-related protein-14 (MRP-14). Their caution is reasonable. However, we have provided additional evidence that MRP-14 is expressed in bone marrow–derived human megakaryocytes and megakaryocytes differentiated in vitro from CD34-positive peripheral blood cells (Data Supplement Figure I of our article¹). We also have detected MRP-8/14 protein in human platelets by flow cytometry (data not shown). Double antibody experiments show costaining for the platelet-specific marker glycoprotein IIb/IIIa and for MRP-8/14. MRP-8/14–positive platelets were negative for the leukocyte marker CD45, ruling out leukocyte contamination as a source of the MRP-8/14 signal.

Disclosures

This study was funded in part by Millennium Pharmaceuticals. Drs Healy, Damokosh, and Lillie and M.D. Pickard, T.L. Dowie, and L. Poisson are employees of Millennium Pharmaceuticals and played roles in the design of the study, data collection, data analysis, data interpretation, and the writing of the report. Drs Simon and Libby report having served as consultants and advisors to Millennium Pharmaceuticals. Dr Ridker is named as a coinventor on patents filed by Brigham and Women’s Hospital that relate to the use of inflammatory biological markers in cardiovascular disease. The other authors report no conflicts of interest.

1. Healy A, Pickard MD, Pradhan AD, Wang Y, Chen Z, Croce K, Sakuma M, Shi C, Zago AC, Garasic J, Damokosh AI, Dowie TL, Poisson L, Lillie J, Libby P, Ridker PM, Simon DI. Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events. Circulation. 2006; 113: 2278–2284.[Abstract/Free Full Text]